Premium
Virologic response with 2 different cidofovir dosing regimens for preemptive treatment of adenovirus DNA emia in pediatric solid organ transplant recipients
Author(s) -
Guerra Sanchez Carlos H.,
Lorica Cherish D.,
Arheart Kristopher L.,
Perez Michelle M.,
Tekin Akin,
Gonzalez Ivan A.
Publication year - 2018
Publication title -
pediatric transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.457
H-Index - 69
eISSN - 1399-3046
pISSN - 1397-3142
DOI - 10.1111/petr.13231
Subject(s) - medicine , dosing , regimen , nephrotoxicity , population , pharmacology , toxicity , environmental health
ADV is frequently seen in our pediatric SOT population. It presents in a variety of clinical presentation and can cause severe disease. In this population, there are very few studies to determine the safety of CDV as a potential therapeutic agent. We present the findings of our retrospective study evaluating the efficacy and safety of CDV as 2 separate dosing regimens. Regimen A uses the standard 5 mg/kg once a week (Regimen A), and the second uses the 1 mg/kg 3 times per week (Regimen B). Overall, the dosing regimen did not differ in nephrotoxicity, but Regimen B had a higher, although non‐significant, rate of viral load clearance. This suggests that more frequent dosing at lower levels may be more efficacious without any significant side effects in our SOT population.